In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to Keytruda alone, following three …
What’s Happening With Moderna Stock?
view original post
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to Keytruda alone, following three …